Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark. Show More...
-
Website https://www.genmab.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 1379.50 DKK
-
Last Updated 28-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share DKK -7.16 -13.28 -10.58 2.16 5.26 12.56 19.22 17.77 23.73 34.03 36.95 Dividends DKK Payout Ratio % * Shares Mil 45.0 45.0 46.0 52.0 57.0 61.0 62.0 62.0 62.0 64.0 65.0 Book Value Per Share * DKK 25.53 11.91 7.32 9.92 33.94 51.05 65.3 89.49 115.45 192.8 221.35 Free Cash Flow Per Share * DKK 6.87 -10.51 -0.39 -3.1 0.58 -0.89 10.36 18.84 9.4 19.96 Return on Assets % -13.67 -29.48 -29.91 6.56 13.1 22.56 25.97 18.64 19.55 18.35 19.66 Financial Leverage (Average) 2.3 3.22 4.42 2.63 1.41 1.12 1.09 1.05 1.06 1.08 1.06 Return on Equity % -27.04 -76.14 -112.03 21.55 22.38 27.67 28.56 19.89 20.61 19.64 20.98 Return on Invested Capital % -23.09 -66.2 -113.15 17.78 20.44 26.63 27.95 19.34 19.81 17.05 18.3 Interest Coverage -2.09 -3.87 -40.91 20.66 74.35 380.63 205.21 223.79 Current Ratio 1.83 1.55 1.4 1.87 4.22 8.85 11.9 18.52 16.77 14.88 19.04 Quick Ratio 1.29 1.19 1.39 1.87 4.22 8.85 11.9 18.52 16.77 14.88 19.04 Debt/Equity 0.010 0.010 0.010 0.010